Ming Cheah
Board Member at TORL BioTherapeutics
San Francisco Bay Area
Overview
Work Experience
Vice President - Life Sciences Investing
2022 - Current
Focused on investments in private-stage, emerging therapeutics companies
Goldman Sachs is a multinational financial services firm providing securities, investment banking, and management services.
Board Member
2024
Board Observer
2024
Attovia Therapeutics develops a pipeline of biotherapeutics for immune-mediated diseases.
Raised $165,000,000.00 from Marshall Wace, Redmile Group, Nextech Ventures, EcoR1 Capital, Logos Capital, venBio Partners, Illumina Ventures, Goldman Sachs Asset Management, Frazier Life Sciences and Cormorant Asset Management.
Board Observer
2023
Septerna is a biotech firm unlocking diverse drug discovery potential in G protein-coupled receptors across various diseases.
Raised $250,000,000.00 from Vertex Ventures HC, Soleus Capital, Biotechnology Value Fund, Driehaus Capital Management, Invus, Catalio Capital Management, RA Capital Management, Woodline Partners, Third Rock Ventures and Goldman Sachs Asset Management.
Board Observer
2023
Principal
2020 - 2022
Investments: Plexium, Exscientia (NAS: EXAI), Vigil Neuro (NAS: VIGL), Obsidian Therapeutics, HotSpot Therapeutics
Board Observer
2022 - 2022
Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.
Raised $272,500,000.00 from Novo Holdings, F-Prime Capital, SR One, Norwest Venture Partners, RiverVest, Rock Springs Capital, Perceptive Advisors, Surveyor Capital, Pivotal bioVenture Partners and Vida Ventures.
Board Observer
2022 - 2022
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Raised $165,000,000.00 from CRV, RA Capital Management, Pappas Capital, DCVC Bio, SoftBank Vision Fund, Pivotal bioVenture Partners, M Ventures, Surveyor Capital, Lux Capital and Neotribe Ventures.
Board Observer
2021 - 2022
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Raised $210,000,000.00 from Pavilion Capital, Revelation Partners, SR One, LSP BioVentures, Monashee Investment Management, B Capital, Atlas Venture, Sofinnova Partners, CaaS Capital Management and Pivotal bioVenture Partners.
Business Development and Competitive Intelligence
2016 - 2020
Led search and evaluation activities for early and clinical stage oncology assets Led teams with direct reports and large cross-functional teams to advise clinical development and commercial strategies for multiple drugs in oncology and neuroscience. Conducted competitive intelligence, market research and forecasting to inform strategic planning.
Genentech specializes in genetic testing and personalized medicine.